Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones.
Treatment with bendroflumethiazide (2.5 mg, twice daily with potassium supplements) in 63 patients with calcium-containing renal stones for a minimum period of 1 year (average duration of treatment 2.6 years) increased the serum urate values in all patients with an average of 90 mumol./l. (conversion factor: 1 mmol. urate = 183 mg.). Despite this the mean urinary urate excretion was unchanged. In the individual patient a systematic effect of therapy was evident since in patients with low pretreatment values the thiazide increased the urate output while in those with the highest levels before therapy it caused a reduction. In most patients there was a reduction of the urate clearance during therapy, which was most evident in those with the highest pretreatment clearance values. In patients with incomplete types of renal acidification defects the same effects were seen on urate metabolism during thiazide treatment as in the other, idiopathic, stone formers. Although the possible role of urate in calcium stone formation has not been definitely settled this study shows that thiazides do not cause hyperuricosuria and hence their beneficial effects on calcium excretion are not counteracted.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood / Q000378:metabolism* / Q000652:urine
D014527:Uric Acid; D001539:Bendroflumethiazide; D002118:Calcium